KRAS mutations are sufficient to initiate premalignant lesions, PanINs; PanINs can progress to locally invasive or metastatic cancer by way of either genomic rearrangements or stepwise acquisition of mutations in suppressor genes (CDKN2A, TP53 and SMAD4). The gene discussed is CDKN2A; the disease is metastatic malignant neoplasm.